Type I interferons in pancreatic cancer and development of new therapeutic approaches
Autor: | Leo J. Hofland, Amber Blaauboer, Kostandinos Sideras, Casper H.J. van Eijck |
---|---|
Přispěvatelé: | Internal Medicine, Surgery |
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Immune system SDG 3 - Good Health and Well-being Interferon Pancreatic cancer Tumor Microenvironment medicine Humans Tumor microenvironment RIG-I business.industry Cancer Hematology Immunotherapy medicine.disease Acquired immune system Pancreatic Neoplasms 030104 developmental biology Oncology 030220 oncology & carcinogenesis Interferon Type I Cancer research Interferons business medicine.drug |
Zdroj: | Critical Reviews in Oncology/Hematology, 159:103204. Elsevier Ireland Ltd |
ISSN: | 1040-8428 |
Popis: | Immunotherapy has emerged as a new treatment strategy for cancer. However, its promise in pancreatic cancer has not yet been realized. Understanding the immunosuppressive tumor microenvironment of pancreatic cancer, and identifying new therapeutic targets to increase tumor-specific immune responses, is necessary in order to improve clinical outcomes. Type I interferons, e.g. IFN-α and –β, are considered as an important bridge between the innate and adaptive immune system. Thereby, type I IFNs induce a broad spectrum of anti-tumor effects, including immunologic, vascular, as well as direct anti-tumor effects. While IFN therapies have been around for a while, new insights into exogenous and endogenous activation of the IFN pathway have resulted in new IFN-related cancer treatment strategies. Here, we focus on the pre-clinical and clinical evidence of novel ways to take advantage of the type I IFN pathway, such as IFN based conjugates and activation of the STING and RIG-I pathways. |
Databáze: | OpenAIRE |
Externí odkaz: |